U.s. fda grants platform technology designation to the viral vector used in srp-9003, sarepta's investigational gene therapy for the treatment of limb girdle muscular dystrophy type 2e/r4

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced that the raavrh74 viral vector used in the investigational gene therapy srp-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2e/r4, has been granted platform technology designation by the u.s. food & drug administration. “this is one of the first programs to receive platform technology designation.
SRPT Ratings Summary
SRPT Quant Ranking